Novo Nordisk A/S (NYSE:NVO) Shares Bought by Albion Financial Group UT

Albion Financial Group UT grew its holdings in Novo Nordisk A/S (NYSE:NVO) by 121.4% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 507 shares of the company’s stock after purchasing an additional 278 shares during the period. Albion Financial Group UT’s holdings in Novo Nordisk A/S were worth $44,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Nisa Investment Advisors LLC lifted its position in Novo Nordisk A/S by 36.4% in the fourth quarter. Nisa Investment Advisors LLC now owns 1,500 shares of the company’s stock valued at $129,000 after buying an additional 400 shares during the last quarter. Genesis Private Wealth LLC purchased a new stake in shares of Novo Nordisk A/S in the 4th quarter valued at approximately $252,000. Beaumont Financial Advisors LLC lifted its holdings in shares of Novo Nordisk A/S by 3.6% in the 4th quarter. Beaumont Financial Advisors LLC now owns 16,616 shares of the company’s stock worth $1,429,000 after acquiring an additional 572 shares during the last quarter. Atomi Financial Group Inc. boosted its position in shares of Novo Nordisk A/S by 4.8% during the 4th quarter. Atomi Financial Group Inc. now owns 32,146 shares of the company’s stock worth $2,765,000 after purchasing an additional 1,473 shares during the period. Finally, Transform Wealth LLC increased its holdings in Novo Nordisk A/S by 6.7% in the 4th quarter. Transform Wealth LLC now owns 95,317 shares of the company’s stock valued at $8,199,000 after purchasing an additional 6,014 shares during the last quarter. 11.54% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research analysts have recently commented on NVO shares. BNP Paribas upgraded Novo Nordisk A/S to a “strong-buy” rating in a research report on Monday, December 2nd. UBS Group raised Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research report on Wednesday, January 8th. BMO Capital Markets reduced their price target on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a research report on Monday, December 23rd. StockNews.com cut shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a report on Sunday, December 29th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $160.00 target price on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. One research analyst has rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $140.20.

Novo Nordisk A/S Stock Down 0.5 %

NVO stock opened at $80.59 on Thursday. Novo Nordisk A/S has a fifty-two week low of $78.17 and a fifty-two week high of $148.15. The company’s 50 day moving average price is $96.63 and its 200 day moving average price is $116.04. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.75 and a current ratio of 0.94. The firm has a market capitalization of $361.65 billion, a price-to-earnings ratio of 26.08, a PEG ratio of 0.89 and a beta of 0.45.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.